Adagene, Palvella gain after FDA Fast Track Designations
Source: SeekingAlpha
2025-12-16 09:24:19 ET
More on Adagene, Palvella Therapeutics
- Palvella Therapeutics: QTORIN Nears Phase 3 Readout For MLM
- Seeking Alpha’s Quant Rating on Adagene ADR
- Historical earnings data for Adagene ADR
- Financial information for Adagene ADR
- Seeking Alpha’s Quant Rating on Palvella Therapeutics
Read the full article on Seeking Alpha
For further details see:
Adagene, Palvella gain after FDA Fast Track Designations
Adagene Inc.
NASDAQ: ADAG
ADAG Trading
7.29% G/L:
$3.09 Last:
9,039 Volume:
$3.03 Open:
ADAG Latest News
ADAG Stock Data
$139,037,247
37,610,753
N/A
7
N/A
Biotechnology & Life Sciences
Healthcare
CN
Suzhou
